Skip to main content

Advertisement

Table 2 Top 10 adverse effects (all grade) associated with pazopanib versus sunitinib

From: Pazopanib has equivalent anti-tumor effectiveness and lower Total costs than Sunitinib for treating metastatic or advanced renal cell carcinoma: a meta-analysis

Adverse effects The number of study Pazopanib group (event/total) Sunitinib group (event/total) RR (95% CI) P value Heterogeneity
I2 (%) P value
Diarrhea 3 378/714 413/1210 1.11 [1.01–1.23] 0.03 11 0.32
Fatigue 3 350/714 542/1190 0.87 [0.79–0.96] 0.006 0 0.64
Hypertension 4 761/1241 783/1747 1.04 [0.99–1.10] 0.15 54 0.09
Nausea/Vomiting 3 434/719 531/1225 0.95 [0.88–1.02] 0.15 80 0.006
Leukopenia 2 258/626 477/648 0.55 [0.50–0.61] <  0.00001 0 0.90
Thrombocytopenia 3 259/719 529/1225 0.54 [0.48–0.60] <  0.00001 0 0.47
Neutropenia 3 227/719 447/1225 0.54 [0.48–0.61] <  0.00001 0 0.57
Increased creatinine 2 190/626 284/648 0.68 [0.59–0.79] <  0.00001 0 0.35
Increased AST 2 359/626 358/648 1.02 [0.93–1.12] 0.67 0 0.96
Increased ALT 2 351/626 266/648 1.35 [1.20–1.51] < 0.00001 11 0.29
  1. Abbreviations: ALT: alanine aminotransferase, AST: aspartate aminotransferase